GSK Raises Prospects For Withdrawn Blood Cancer Drug Blenrep To Return To US Market - Here's Why
On Thursday, GSK plc (NYSE:GSK) released headline results from a planned interim analysis of the DREAMM-7 head-to-head phase ...
BioSpace19h
GSK Builds Case for Blenrep with Multiple Myeloma OS Data That Bests J&J’s Darzalex
GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects multi-blockbuster ...
GSK Reports Positive Headline Results From DREAMM-7 Phase III Trial
GSK plc (GSK, GSK.L), on Thursday, announced positive headline results from a planned interim analysis of the DREAMM-7 head-to-head ...
pharmaphorum5d
Is GSK’s Blenrep heading for a renaissance?
The pharma group reported top-line results from the DREAMM-7 study this morning, showing a greater benefit for Blenrep (belantamab mafodotin) compared to Genmab and Johnson & Johnson’s anti-CD37 ...
pharmaphorum3d
GSK backs up its Blenrep rehab bid with survival data
The data from the DREAMM-7 study shows that Blenrep (belantamab mafodotin) was more effective at extending overall survival (OS) than Genmab and Johnson & Johnson’s anti-CD37 therapy Darzalex ...
MT Newswires on MSN15h
European Equities Close Higher in Thursday Trading; EU GDP Rises in Q3
The European stock markets closed higher in Thursday trading as The Stoxx Europe rose 1.08%, Germany's DAX climbed 1.26%, the FTSE in London was up 0.51%, France's CAC advanced 1.32%, and the Swiss ...
AL Amyloidosis Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers
The leading AL Amyloidosis Companies such as Caelum Biosciences, Nexcella, Inc., HaemaLogiX Ltd., Prothena, ZENTALIS ...